The disclosure relates to radiolabelled imidazole glutaminyl cyclase (QC) inhibitors for use as imaging agents. The disclosure also relates to pharmaceutical compositions comprising these compounds and the use of these compounds for imaging and detection in neurological disorders, such as Alzheimer&rsquos disease, Familial British Dementia, Familial Danish Dementia, Down Syndrome and Huntington&rsquos disease.
